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Abstract
Background: Targeted and stringent measures of tuberculosis prevention are necessary to achieve the goal of tuberculosis
elimination in countries of low tuberculosis incidence.
Methods:We ascertained the knowledge about tuberculosis risk factors and stringency of tuberculosis prevention measures
by a standardized questionnaire among physicians in Germany involved in the care of individuals from classical risk groups
for tuberculosis.
Results: 510 physicians responded to the online survey. Among 16 risk factors immunosuppressive therapy, HIV-infection
and treatment with TNF-antagonist were thought to be the most important risk factors for the development of tuberculosis
in Germany. Exposure to a patient with tuberculosis ranked on the 10th position. In the event of a positive tuberculin-skin-
test or interferon-c release assay only 50%, 40%, 36% and 25% of physicians found that preventive chemotherapy was
indicated for individuals undergoing tumor necrosis factor-antagonist therapy, close contacts of tuberculosis patients, HIV-
infected individuals and migrants, respectively.
Conclusions: A remarkably low proportion of individuals with latent infection with Mycobacterium tuberculosis belonging to
classical risk groups for tuberculosis are considered candidates for preventive chemotherapy in Germany. Better knowledge
about the risk for tuberculosis in different groups and more stringent and targeted preventive interventions will probably
be necessary to achieve tuberculosis elimination in Germany.
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Introduction
Tuberculosis (TB) remains a major global health problem. In
2012, an estimated 8.6 million people developed TB and 1.3
million died from the disease (including 320,000 deaths among
HIV-positive people) [1]. However in most of the low-prevalence
countries in Western Europe and North America overall
notification rates for TB have been declining for the last decades.
With a total incidence of 5.3 cases per 100,000 population in 2011,
TB has become a rare disease in Germany [2].
Due to the current absence of vaccines for the prevention of TB
with a higher efficiency than the Mycobacterium bovis Bacille
Calmette Gue´rin (BCG) vaccine, TB control primarily relies on
the prevention of transmission of active TB by identification and
treatment of patients with active disease. In order to further reduce
transmissions rates and ultimately eradicate TB, low incidence
countries such as Germany eventually rely on contact investiga-
tions by public health services and physicians for active case
finding and identification of contacts with latent infection with
Mycobacterium tuberculosis (LTBI) [3,4].
In clinical practice, LTBI is defined by the presence of an
adaptive immune response to antigens specific for M. tuberculosis,
ascertained by a positive tuberculin-skin-test (TST) or interferon-c
release assay (IGRA) result, in the absence of active TB [4].
According to the Infection Protection Act (IFSG) in Germany
close contacts of TB patients are required to be subject to a TST
or IGRA testing by the public health authorities [5]. In case of
positive test results national recommendations suggest preventive
chemotherapy with isoniazid for a duration of nine months [6]. A
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contact person with LTBI will usually be referred to a private
physician with the recommendation to initiate preventive chemo-
therapy [7]. In contrast to neighboring Switzerland [8], most of
the contacts with LTBI referred to private pulmonologists or
general practitioners in Germany by the public health authorities
are left untreated. A recent survey in the state of Lower Saxony
demonstrated that only 29% of healthy contacts with a positive
TST or IGRA test result at the time of contact investigation
received preventive chemotherapy [9]. In a large observational
cohort study performed by the public health authorities in the city
of Hamburg, even under study conditions only 21% of contacts
with LTBI received preventive chemotherapy [10]. The low
acceptance of preventive chemotherapy contradicts the expenses
and efforts by the public health authorities in Germany to identify
individuals at risk for the future development of TB.
To develop a basis for improvement of TB prevention we aimed
to gain a better insight about the knowledge of physicians working
within the German health care system about risk factors for TB
and their attitude towards preventive chemotherapy.
Materials and Methods
To evaluate the knowledge and attitude of physician decision
makers in Germany about current methods for the diagnosis of
LTBI and preventive chemotherapy, we developed a standardized
questionnaire that was initially revised by two independent
international reviewers. Feasibility of this survey tool was
evaluated in an anonymized pilot study involving distribution of
paper questionnaires to 500 physicians. The return rate by mail
was 130 questionnaires (26%). Results from the feasibility study
were not included in the final analysis. Upon the experience with
the pilot survey, it was decided to distribute the questionnaire by
email via an internet-link leading to a web-based survey platform
(www.surveymonkey.com). Instructions about the study back-
ground, design and participation were found in the study
invitation and on the web-based survey platform. In February
2012 email invitations were send to physicians from the registries
of the German Society for Pulmonology (DGP e.V.), the German
working group of private physicians caring for HIV-infected
patients (DAGNA¨ e.V.), the network for rheumatic diseases
(DGRh), the German network of occupational medicine physi-
cians (ArbMedNet), and to TB officers at municipal or regional
health care departments in Germany. Physicians were asked to
participate in the survey within 30 days of notice. In order to
ensure the participants anonymity the gathered results were
encrypted by an independent code system.
The web-based questionnaire was composed of 8 main parts
with 26 questions and a free commenting section for further
remarks:
Part 1: Six single item questions about specific data of participating
physicians (age, working area, expertise and patients collective).
Part 2: Three single item questions about past, current and future
use and evaluation of diagnostic tools for LTBI such as TST and/
or IGRAs.
Part 3: One multiple answer question with the opportunity to
select three risk groups among sixteen options to estimate the risk
of patients at risk for developing TB if diagnostic tools are positive.
Part 4: Five single item questions concerning risk groups and the
implementation of national guidelines towards LTBI (offering
testing and treatment to patients at risk).
Part 5: One single item question about favored therapy regimes for
patients with LTBI.
Part 6: Nine questions about the attitudes of physicians towards
TB prevention in Germany using six-point adjectival scales that
included the response categories full and minimal agreement.
Part 7: One single item question about the necessity of
improvement towards management of LTBI using a ranking scale
in order to prioritize between diagnostics, period of therapy and
effectiveness.
Eligible respondents included physicians who were involved in
the diagnosis and/or therapy of LTBI. We excluded physicians
who had no contact to a suspected case LTBI within the last 12
months.
Statistical analysis
The collected data consisted only of categorical variables. They
were summarized using frequencies and percentages.
The paired sample McNemar Test was used to test the
difference of proportions between past and future application of
several diagnostic devices by German physicians (sample size
N= 510). All tests were two-sided. A difference was considered
statistically significant when the p-value was smaller than 0.05. All
p-values were adjusted according to Bonferroni.
In addition to the p-values 95% confidence intervals (95% CI)
for differences between past and future applications were
calculated.
All data were analyzed using SPSS 19.0 for Windows (SPSS
Inc., Chicago, Illinois, USA) and BIAS 9.16 for Windows (epsilon-
Verlag; Dr. rer. med H. Ackermann, Goethe-University Frank-
furt/Main, Germany).
The study was reviewed and approved by the Ethical Board of
the University of Lu¨beck (#14-167). The study was a voluntary
survey of German physicians and all data entered and analyzed
were anonymous. There were no patients involved and consent
from physicians providing data anonymously was not required.
We have been in touch with the Ethical Board at the University of
Lu¨beck and have received the written information that the Ethical
Board of the University of Lu¨beck has no reservations against
publication of the study results.
Results
Characteristics of German physicians participating in the
survey
We contacted 1840 pulmonologists and 354 public health
officers directly via email requesting participation in the survey. In
addition, approximately 1000 rheumatologists, physicians caring
for HIV-infected patients and physicians working in occupational
medicine were addressed via the DGRh, DAGNA¨ and ArbMed-
Net email registers. 510 physicians responded to the survey
(table 1). Only 15.2% (n= 76) of participating physicians were
under the age of 40 and 6.0% (n= 30) were older than 60 years of
age. More than one third (38.5%/n=190) of the participating
physicians were working in a hospital setting and almost one
quarter (23.9%/n=118) were working in a private practice. One-
hundred and thirty-four physicians (26.3%) were employed as TB
officers at municipal or regional health care departments and
11.5% (n= 55) of the physicians were working in the field of
occupational medicine. Overall, 250 participants (49.0%) were
specialized as pulmonologists.
Experience and future intention to use different tests for
diagnosing LTBI
The changes of the attitude towards the methods for the
diagnosis LTBI are shown in table 2. Physicians intend to use the
TB Prevention in Germany
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ELISPOT IGRA (T-Spot.TB test) significantly more often and the
TST significantly less often in the future when compared to the
past. There is no significant change in the anticipated behavior for
the use of the ELISA IGRA (QFT-GIT test) which is already in
frequent use in the county.
Estimated risk by physicians for persons at risk to
develop TB
When physicians were asked to prioritize groups with the
highest risk for the future development of TB, patients with an
immunosuppressive therapy, HIV-seropositive patients and pa-
tients with a TNF-antagonist-therapy, were ranked on positions 1–
3 among 16 risks groups (figure 1-right). Interestingly, contact
persons of patients diagnosed with TB were ranked on position
10/16. Physicians’ attitude of groups at risk for the future
development of TB and data from the published literature
(figure 1-left) did not match.
Intensity of testing vs. intensity of treatment
The majority of physicians recommend immunodiagnostic
testing for LTBI (figure 2). For close contacts of patients with
TB 94% of pulmonologist and 91% of non-pulmonologists suggest
Table 1. Characteristics of German physicians participating in the survey.
Physicians data Frequency Percent (%) n
Age 21–30 years 8 1.6 501
31–40 years 68 13.6
41–50 years 205 40.9
51–60 years 190 37.9
.60 years 30 6.0
Work Place Established
practitioner
118 23.9 493
Teaching hospital 99 20.1
Non-teaching Hospital 49 10.0
University Hospital 42 8.5
Other 185 37.5
Specialty Internal Medicine 236 49.2 480
General Practitioners 26 5.4
Occupational Medicine 55 11.5
Other 163 33.9
Subspecialisation Respiratory Medicine 250 49.0 510
Public Health
Medicine
134 26.3
Other 81 15.9
none 45 8.8
doi:10.1371/journal.pone.0112681.t001
Table 2. Experience and future intention to use different tests for diagnosing latent infection with Mycobacterium tuberculosis.
Diagnostic device Past Future Difference
95% CI for
difference p-value
p-value
adjusted
p1 p2 p1–p2
Tuberculin-Skin-Test 57.1% 34.1% 23% [18.6; 27.3] ,0.001* ,0.001*
IGRA QuantiFeron
Gold in tube
69.4% 67.7% 1.7% [–1.2; 4.7] 0.298 1.000
IGRA T-Spot.TB 27.5% 32.2% –4.7% [–7.9; 21.5] 0.005* 0.0196*
Other technologies
(e.g. flow cytometry)
5.9% 4.5% 1.4% [–0.2; 2.9] 0.143 0.572
The sample size was N= 510.
p1: percentage of physicians using the corresponding test in the past.
p2: percentage of physicians using the corresponding test in future.
p1–p2: difference of percentages p1 and p2.
95% CI: 95% confidence interval for difference.
p-value: paired sample McNemar Test to test the difference of proportion between past and future application of several diagnostic devices by german physicians.
p-value adjusted: adjusted p-value according to Bonferroni.
The asterisk (*) indicates significant differences.
doi:10.1371/journal.pone.0112681.t002
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testing. Similar results can also be observed for other risk groups
such as patients undergoing TNF-antagonist therapy or migrants.
However, there is a substantial discrepancy between the intention
to test and the intention to treat. Physicians in Germany intend to
treat only 50% of individuals undergoing TNF-antagonists
therapy, 40% of close contacts of patients with TB, 36% of
individuals with HIV-infection and 25% of migrants with a
positive result in the TST and/or IGRA. Remarkably, for most
risk groups no difference can be identified in the attitudes of
pulmonologists vs. non-pulmonologists towards the intention to
treat. The only significant difference was found towards individ-
uals with HIV-infection and those undergoing immunosuppressive
therapy.
Choice of preventive treatment of latent infection with
M. tuberculosis
Physicians were able to choose between five different TB
preventive treatment regimens or enter manually a treatment
regime of their choice. Three hundred and sixty-two of 510 (71%)
physicians answered the questions. The preferred preventive
treatment is isoniazid for 9 months (n = 194; 54.4%), followed by
isoniazid for 6 months (n = 85; 23.5%) and treatment with the
combination of daily treatment with isoniazid and rifampicin for 3
months (n = 46; 12.7%). Fifteen physicians (4.1%) favored daily
treatment with isoniazid monotherapy for 12 months and 5
physicians (1.4%) daily treatment with rifampicin monotherapy for
4 months. Fourteen physicians (3.9%) entered alternative treat-
ment options.
Attitudes of decision makers towards TB prevention
Participants had the opportunity to express their attitudes by
answering nine questions (q1–q9) concerning TB prevention and
treatment (table 3). While 81.1% of the physicians agree that
immunodiagnostic testing for LTBI in risk groups and treatment of
individuals with a positive test result is an efficient method of TB
prevention, more than 30% disagree to the principle ‘‘intention to
test is intention to treat!’’. The physicians who responded in the
survey agreed that more than 40% of physicians and more than
55% of patients have no insight into the efficacy of preventive
treatment. A large proportion of physicians (58.4%) and patients
(69.0%) are thought to be hesitant to enter treatment for fear of
adverse drug events.
Measures to improve TB prevention
Finally, physicians were asked to prioritize three statements
concerning optimizing TB prevention. Most physicians (n = 173;
57.5%) favored improvements in the diagnostics of LTBI, while
there was an equal proportion of physicians that favored a stronger
efficacy of preventive treatment regimens (n = 129; 41%) or
improvements to shorten the duration of preventive chemotherapy
(n= 117; 39%).
Discussion
TB has become a rare disease in Germany and most other
Western European Countries. As the World Health Organization
(WHO) and the European Center for Disease Prevention and
Control (ECDC) now aim for TB elimination [11,12], prevention
of TB will focus especially on risk groups. However, currently
available tests are poor prognostic markers for the identification of
individuals who will develop TB in the future and the definitions of
‘‘risk groups for TB’’ are not universally applicable [13,14].
We evaluated the knowledge about TB risk factors and attitudes
towards TB prevention among physicians involved in TB
prevention and care in Germany. The key findings of this study
are a surprisingly low proportion of individuals with LTBI
belonging to classical risk groups for TB receiving preventive
therapy and substantial gaps in the knowledge on the risk for TB
in a country of low TB incidence resulting in uncertainties and
non-stringent management of TB prevention.
Pulmonologists are more likely to note that physicians have no
insight into the efficacy of preventive therapy than non-pulmo-
Figure 1. Subjective ranking (1=highest risk; 16= lowest risk) of risk groups for the future development of tuberculosis according
to German physicians involved in LTBI testing (left) in comparison with the range of reported relative risks (RR) for the
development of tuberculosis in the same risk groups according to published studies ranked according to the highest risk reported
(right). References are shown in square brackets (max. to min.) [39–70]. *Risk is expressed as relative risk for cohort studies or controlled trials, odds
ratio for case-control studies and incidence rate ratio when incidence in cases was compared to that in the general population. In the case of
migrants the highest value for risk is not plotted on the graph (relative risk of 315.5). TNFa – tumor necrosis factor a, SOT – solid organ transplant, JJI
bypass – jejunoileal bypass, IVDU – intravenous drug users, BMT – bone marrow transplant, IS therapy – immunosuppressive therapy, Rx –
radiological.
doi:10.1371/journal.pone.0112681.g001
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nologists. This is likely due to the better knowledge of pulmonol-
ogists on tuberculosis, compared to non-pulmonologists. Although
pulmonologists are more motivated to test HIV-infected individ-
uals and other immunocompromised hosts for LTBI compared to
non-pulmonologists, and they are better aware of the gaps in TB
control in Germany, stringency to provide preventive chemother-
apy for individuals with positive test results is lacking in all groups
of professionals.
In the absence of available data from Germany, national
recommendations for TB contact tracing [7] report that people
living with HIV-infection (PLWH) have a risk of developing active
TB of 35–162 per 1000 person-years. However these data
originate from studies conducted before the advent of modern
antiretroviral therapies (ART) [15] and refer to high prevalence
countries of TB, where M. tuberculosis exposure for PLWH is
much higher than in Germany. Results from the Swiss HIV cohort
reported a lower incidence of active TB of 16 per 1000 person-
years in TST positive individuals in the absence of preventive
therapy [16]. Furthermore, the country of origin was of substantial
importance for the risk of TB in that study. In Switzerland the
number of PLWH with a positive TST or IGRA test result who
needed to be treated to prevent a case of TB was 4 times higher for
migrants from high incidence countries of TB compared to
individuals originating from low incidence countries of TB [16].
The lower risk of PLWH for developing active TB in low-
prevalence settings is likely related to a decreased risk of M.
tuberculosis transmission from individuals with active disease,
while in high-incidence countries the risk of M. tuberculosis
exposure is considerably greater.
Additionally, in a low incidence setting, ART initiation leads to
a 44–56% risk reduction of active TB [16,17]. PLWH predom-
inantly receive their care from specialized outpatient clinics or
private practitioners in Germany. More than 80% of PLWH in
the country have suppressed levels of viral replication on ART
[18] and active TB in these patients has become a very rare
opportunistic infection [19] even in the absence of preventive
therapy. Persistent viral replication was also associated with a
higher risk of developing TB in a large French cohort of PLWH
[20]. Another recent study reporting on the German HIV cohort
describes an important decrease in TB occurrence after ART
initiation. The authors also suggest that country of origin and the
degree of immunosuppression are also associated with the risk of
developing TB. Preventive therapy was given to only a very small
fraction of the population and the authors suggest a differentiated
approach in ascertaining the risk of future TB and therefore the
indication LTBI screening and preventive therapy within this
population [21]. It is likely that because of the personal experience
of physicians caring for PLWH in Germany caretakers regularly
evaluate only two thirds of PLWH for LTBI and only one third of
those with a positive TST or IGRA result receives preventive
therapy in the present study.
Similarly, the current recommendations for TB contact tracing
in Germany describe a relative risk of 37–74 for the development
of TB in solid organ transplant recipients. However, in a large
retrospective cohort study of lung transplant patients from
Germany totaling over 7000 person-years of follow-up, only 5
patients were diagnosed with active TB corresponding to relative
risk of 7.5–10 times lower than indicated, in this population [22].
In our survey, only one third of physicians indicated that they
offered preventive chemotherapy to immuno-suppressed patients,
e.g. solid organ transplant recipients.
Until recently, one of the dogmas of immunodiagnostic testing
by TST and IGRAs in individuals from risk groups was ‘‘intention
to test is intention to treat’’ [23]. Healthcare workers (HCW) with
a positive IGRA test result in countries of low TB incidence were
thought to be at risk for the development of TB and were offered
preventive chemotherapy. However, there is substantial within-
subject variability on serial testing [24] and positive IGRA test
Table 3. Attitudes of German physicians involved in LTBI testing and/or the decision for the initiation of tuberculosis preventive
chemotherapy.
Questions towards decision makers concerning tuberculosis
prevention Agreement
Chi-Square Test
p-value
Pulmonologists Non Pulmonologists All
q1 Testing persons at risk with TST/IGRA and treating
individuals with a positive test result is
an efficient method of prevention.
78.3% (n = 148) 84.1% (n = 143) 81.1% (n = 291) 0.179
q2 ‘‘Intention to test is intention to treat!’’ 67.4% (n = 128) 71.6% (n = 121) 69.4% (n = 249) 0.423
q3 A risk analysis through TST and/or
IGRA should be performed with all
individuals belonging to a risk group
66.8% (n = 125) 68.3% (n = 114) 67.5% (n = 239) 0.821
q4 ‘‘Tuberculosis is on the decline in
Germany and prevention is not necessary anymore!’’
14.9% (n = 28) 14.4% (n = 24) 14.7% (n = 52) 1.000
q5 ‘‘A positive test result (TST/IGRA)
has no significance to me!’’
19.4% (n = 36) 14.3% (n = 24) 16.9% (n = 60) 0.256
q6 Physicians have no insight into the
efficacy of preventive treatment
50.0% (n = 94) 30.5% (n = 50) 40.9% (n = 144) 0.0002*
q7 Physicians avoid to administer
preventive treatment for the risks
of side effects
61.9% (n = 117) 54.5% (n = 91) 58.4% (n = 208) 0.163
q8 Patients have no insight into the
efficacy of preventive treatment
56.8% (n = 108) 54.5% (n = 91) 55.8% (n = 199) 0.671
q9 Patients hesitate to enter preventive
treatment for the fear of side effects
70.2% (n = 134) 67.7% (n = 113) 69% (n = 247) 0.648
doi:10.1371/journal.pone.0112681.t003
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results revert to negative in a substantial proportion of HCW in
the absence of preventive chemotherapy [25]. In a recent study
from North America with more than nine thousand healthcare
workers of which 1223 had positive IGRA test results, one third
had reversion to a negative test result on follow-up and none of the
HCW developed tuberculosis, in the absence of preventive
chemotherapy [26]. Therefore the benefit of preventive therapy
in HCW with positive IGRA results in the absence of a
documented recent exposure to an active case or additional risk
factors for TB is unclear. Preventive treatment of HCW with
evidence of LTBI without evidence of recent exposure is no more
recommended in Germany but can be considered in cases who
had a documented contact with an index case, similar to contacts
in the general population [27].
National recommendations for TB contact tracing also report
that the risk of patients with silicosis to be 30 times elevated [7]. In
a study on 118 retired coal miners in Germany, almost 40% with
silicosis, approximately 50% had a positive IGRA test result. None
of the 90 individuals who were evaluated after 2 years in follow-up
developed active tuberculosis in the absence of preventive
chemotherapy [28].
More than one third of close contacts of patients with
contagious TB can be identified as having LTBI [29]. In the
absence of preventive chemotherapy the risk of close contacts with
positive TST results to progress to active disease has been
estimated around 2–6% during the first 2–3 years after exposure
[13,30]. However two studies report progression rates to active TB
of 12–13% in close contacts with positive IGRA test results not
receiving preventive chemotherapy [10,31]. It is thus possible, that
close contacts are the group with the highest risk for the
progression to TB in Germany. Other studies also suggest that
the risk in contacts of TB patients and particularly in household
contacts is underestimated [32]. Given the fact that LTBI testing
of close TB contacts is mandatory in Germany according to the
Infection Protection Act the low acceptance rate documented in
this survey (Fig. 2), confirming recent observations, is surprising
[9,23].
In order to improve TB prevention and to achieve the goal of
TB elimination in countries of low TB incidence the indication for
preventive chemotherapy should be made on a risk assessment-
based approach where the need to screen individuals is prioritised
on the basis of the intensity of exposure and susceptibility of
individuals for M. tuberculosis infection [3]. Additionally, due to
the low positive predictive value, LTBI-testing should not be
directed at individuals with a low risk of active TB in whom the
risks of preventive chemotherapy may outweigh its benefits. It has
been suggested that over 95% of individuals with a positive IGRA
or TST do not develop active TB during follow-up further
supporting targeted testing [33].
Rather surprisingly we found that physicians in Germany did
not rank migrants among the groups with a high risk for TB,
although it is recognized that individuals coming from high TB
prevalence countries who are latently infected might have an
increased risk of active TB of more than 13-fold in comparison
with migrants without LTBI [34]. Other studies also report
insufficient testing coverage of migrants for LTBI [35].
Even though preventive therapy is highly effective in selected
populations, acceptance and adherence to a prolonged treatment
are less than optimal and adverse effects, although rare, can occur
in a small proportion of individuals. Mistrust against preventive
strategies might explain the suboptimal acceptance rates for
preventive therapy among both patients and prescribing physi-
cians with even lower acceptance rates being recorded among
HCW. On the other hand, the long duration of therapy might lead
to poor adherence with fewer than half of the individuals started
on preventive therapy completing the entire course according to
one study [36]. Consequently in the low-prevalence setting, the
decision for preventive treatment should be based on an
individualized risk-benefit assessment [37,38].
Figure 2. Rate of performed tests (IGRA/TST) and preventive treatment offered in the case of a positive test result in risk groups
among pulmonologists and non-pulmonologists involved in TB prevention in Germany. P – pulmonologists; NP – non-pulmonologists;
TNFa – tumor necrosis factor a; IS therapy – immunosuppressive therapy, IGRA – interferon gamma release assay; TST – tuberculin skin test, PT –
preventive chemotherapy.
doi:10.1371/journal.pone.0112681.g002
TB Prevention in Germany
PLOS ONE | www.plosone.org 6 November 2014 | Volume 9 | Issue 11 | e112681
This study has several limitations. Physicians’ behavior was not
directly analyzed but attitude of behavior was evaluated. It is
possible, that actual behavior differs from the stated attitudes.
Although the survey was distributed among a large group of
decision makers and caretakers of TB patients in Germany from
the public health care sector and different clinical areas and 510
physicians completed the online survey, the response rate of the
electronic questionnaire was only approximately 20%. Due to the
anonymous nature of this web-based survey, no information was
available on the physicians who responded or did not respond to
the invitation to participate in the study. Consequently, sampling
bias cannot be excluded and generalization of the results has to be
made with caution. Despite these limitations, this is the largest
survey of physicians’ attitude towards TB prevention in Germany
to date and the results from this survey reflect actual data on
acceptance of preventive chemotherapy in this country.
In conclusion, we found great uncertainty about risk factors for
tuberculosis among physicians in Germany likely leading to non-
stringent behavior in TB prevention. TB prevention could be
improved if the definition of TB ‘‘risk groups’’ for LTBI screening
and preventive chemotherapy will be re-classified according to
data applying to local situations. Immunodiagnostic testing should
be limited to risk groups in which a positive test result is associated
with a significantly increased risk for developing TB in the future
and significant risk reduction can be achieved by preventive
chemotherapies. This will require regional and national surveys
rather than applying information from high TB prevalence
countries to countries of low TB prevalence and vice versa. This
approach could lead to more consequent initiation of preventive
therapy following a positive test and avoid unnecessary testing and
treatment.
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